BURLINGAME, Calif., May 17 /PRNewswire/ -- BioSeek, Inc., a leader in applying integrated human biology systems for developing new therapeutics, announced today that it has entered into a non-exclusive agreement with Boston Scientific Corporation to profile compounds for potential applications in new products.
BioSeek has previously demonstrated that its proprietary BioMAP(R) Systems can identify key biological activities of compounds that correlate with clinical efficacy. Under the current agreement with Boston Scientific, which expands earlier collaborations between the companies, BioSeek will screen and evaluate a series of compounds (selected by Boston Scientific) for novel therapeutic uses. Financial terms were not disclosed.
“Our agreement with Boston Scientific represents an important extension in the scope of our BioMAP technology applications beyond traditional drug discovery settings,” commented Peter Staple, chief executive officer of BioSeek. “This relationship brings together BioSeek’s powerful systems for discovering new therapeutic uses of compounds with Boston Scientific’s leadership in devices and interventional medicine. We’re very pleased to take this productive relationship to a further stage of collaboration.”
About BioSeek
BioSeek is improving the success rate of pharmaceutical research and development by integrating human biology from the early stages of drug discovery onward. The Company’s BioMAP(R) Systems incorporate predictive human cell-based disease models that generate uniquely informative activity signatures for each potential drug, driving the selection and development of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology in collaborations to enhance the productivity of its pharmaceutical partners’ pipelines, and in the Company’s internal programs to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular diseases, autoimmune diseases and related indications.
For more information, go to www.bioseekinc.com
BioSeek, Inc.
CONTACT: Peter D. Staple, Chief Executive Officer of BioSeek, Inc.,+1-650-552-0728; or Kari Watson of MacDougall Biomedical Communications,+1-508-647-0209 or kwatson@macbiocom.com, for BioSeek, Inc.
Web site: http://www.bioseekinc.com//
